AstraZeneca Fights Damages In Drug Pricing Suit

Law360 (August 7, 2007, 12:00 AM EDT) -- On the heels of a similar bid by Warrick Pharmaceuticals Corp., AstraZeneca Pharmaceuticals LP has rejected a request that it shell out treble damages to two classes in the average wholesale price litigation, arguing that such a remedy is unwarranted.

AstraZeneca said in court documents filed Monday that the court’s findings did not support a conclusion that the drug giant had acted with malice or with the level of callousness necessary to justify the extraordinary remedy of treble damages.

The plaintiffs revealed their final damages calculations...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Citizens for Consume, et al v. Abbott Laboratories,, et al


Case Number

1:01-cv-12257

Court

Massachusetts

Nature of Suit

Anti-Trust

Judge

Patti B. Saris

Date Filed

December 19, 2001

Law Firms

Companies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.